title: Portal application of autologous CD133+ bone marrow cells to the liver: a novel concept to support hepatic regeneration.
abstract: The liver has a large capacity for regeneration after resection. However, below a critical level of future liver remnant volume (FLRV), partial hepatectomy is accompanied by a significant increase of postoperative liver failure. There is accumulating evidence for the contribution of bone marrow stem cells (BMSCs) to participate in liver regeneration. Here we report on three patients subjected to intraportal administration of autologous CD133(+) BMSCs subsequent to portal venous embolization of right liver segments, used to expand left lateral hepatic segments as FLRV. Computerized tomography scan volumetry revealed 2.5-fold increased mean proliferation rates of left lateral segments compared with a group of three consecutive patients treated without application of BMSCs. This early experience with portovenous application of CD133(+) BMSCs could suggest that this novel therapeutic approach bears the potential of enhancing and accelerating hepatic regeneration in a clinical setting.
authors.affiliation: Department of General Surgery, Heinrich-Heine-University of Duesseldorf, Moorenstrasse 5, D-40225 Duesseldorf, Germany.
authors.forename: Jan Schulte
authors.initials: JS
authors.lastname: am Esch
authors.forename: Wolfram Trudo
authors.initials: WT
authors.lastname: Knoefel
authors.forename: Michael
authors.initials: M
authors.lastname: Klein
authors.forename: Ali
authors.initials: A
authors.lastname: Ghodsizad
authors.forename: Guenter
authors.initials: G
authors.lastname: Fuerst
authors.forename: Ludger W
authors.initials: LW
authors.lastname: Poll
authors.forename: Christoph
authors.initials: C
authors.lastname: Piechaczek
authors.forename: Elmar R
authors.initials: ER
authors.lastname: Burchardt
authors.forename: Niko
authors.initials: N
authors.lastname: Feifel
authors.forename: Volker
authors.initials: V
authors.lastname: Stoldt
authors.forename: Marcus
authors.initials: M
authors.lastname: Stockschläder
authors.forename: Nikolas
authors.initials: N
authors.lastname: Stoecklein
authors.forename: Roy Y
authors.initials: RY
authors.lastname: Tustas
authors.forename: Claus F
authors.initials: CF
authors.lastname: Eisenberger
authors.forename: Matthias
authors.initials: M
authors.lastname: Peiper
authors.forename: Dieter
authors.initials: D
authors.lastname: Häussinger
authors.forename: Stefan B
authors.initials: SB
authors.lastname: Hosch
mesh_terms: D000071916:AC133 Antigen; D000368:Aged; D015703:Antigens, CD / Q000378:metabolism*; D001854:Bone Marrow Cells / Q000166:cytology / Q000378:metabolism*; D016026:Bone Marrow Transplantation / Q000009:adverse effects; D004621:Embolization, Therapeutic; D005260:Female; D006023:Glycoproteins / Q000378:metabolism*; D006498:Hepatectomy; D006801:Humans; D008113:Liver Neoplasms / Q000473:pathology / Q000601:surgery / Q000628:therapy*; D008115:Liver Regeneration; D008297:Male; D008875:Middle Aged; D010455:Peptides / Q000378:metabolism*; D011169:Portal Vein; D014182:Transplantation, Autologous
chemical_list: D000071916:AC133 Antigen; D015703:Antigens, CD; D006023:Glycoproteins; C000606023:PROM1 protein, human; D010455:Peptides